Disease Models
Recapitulate inherited diseases in human engineered cardiac tissues
In vitro disease models enable mutation and patient-specific disease phenotyping and assessment of therapies in the context of human cells. Propria engineers and profiles hEHTs from human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes harboring disease-associated mutations.
Engineer the disease model:
- Start with our lines: In-house lines of the hypertrophic cardiomyopathy mutation MYH7 R403Q and isogenic control
- Send us hiPSCs: Prorpia differentiates customer hiPSC lines to cardiomyocytes to form hEHTs
- Send us cardiomyocytes: Propria uses cryopreserved cells to form hEHTs
Understand the phenotype:
- Baseline contractile characteristics
- Length-dependent, frequency-dependent, compound-dependent deficits of disease hEHTs
Assess therapeutic efficacy:
- Chronic or acute small molecule treatment
- Oligonucleotide therapies, including AAVs, ASOs, and siRNAs
Click the link below to view data from Propria's MYH7 R403Q hEHTs, presented at the 2023 Heart Development & Disease Keystone Symposium:
Recapitulating Hypertrophic Cardiomyopathy in MyoPod® 3D Human Engineered Heart Tissues